United States Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data

United States US: PFE: Revenue (External): Essential Health Product: International

2015 - 2018 | Quarterly | USD th | Pfizer Incorporation

US: PFE: Revenue (External): Essential Health Product: International data was reported at 10,238,000.000 USD th in Sep 2018. This records an increase from the previous number of 6,891,000.000 USD th for Jun 2018. US: PFE: Revenue (External): Essential Health Product: International data is updated quarterly, averaging 8,591,500.000 USD th from Jun 2015 to Sep 2018, with 14 observations. The data reached an all-time high of 14,836,000.000 USD th in Dec 2015 and a record low of 3,220,000.000 USD th in Mar 2017. US: PFE: Revenue (External): Essential Health Product: International data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Last Frequency Range
6,891,000.00 Jun 2018 quarterly Jun 2015 - Jun 2018

View United States's US: PFE: Revenue (External): Essential Health Product: International from Jun 2015 to Jun 2018 in the chart:

United States US: PFE: Revenue (External): Essential Health Product: International

United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU

2015 - 2018 | Quarterly | USD th | Pfizer Incorporation

US: PFE: Revenue (External): Essential Health Product: International: Developed EU data was reported at 2,340,000.000 USD th in Sep 2018. This records an increase from the previous number of 1,591,000.000 USD th for Jun 2018. US: PFE: Revenue (External): Essential Health Product: International: Developed EU data is updated quarterly, averaging 2,277,000.000 USD th from Jun 2015 to Sep 2018, with 14 observations. The data reached an all-time high of 4,442,000.000 USD th in Dec 2015 and a record low of 778,000.000 USD th in Mar 2018. US: PFE: Revenue (External): Essential Health Product: International: Developed EU data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Last Frequency Range
1,591,000.00 Jun 2018 quarterly Jun 2015 - Jun 2018

View United States's US: PFE: Revenue (External): Essential Health Product: International: Developed EU from Jun 2015 to Jun 2018 in the chart:

United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU

United States US: PFE: Revenue (External): Essential Health Product: International: Developed Rest of World

2015 - 2018 | Quarterly | USD th | Pfizer Incorporation

US: PFE: Revenue (External): Essential Health Product: International: Developed Rest of World data was reported at 2,123,000.000 USD th in Sep 2018. This records an increase from the previous number of 1,402,000.000 USD th for Jun 2018. US: PFE: Revenue (External): Essential Health Product: International: Developed Rest of World data is updated quarterly, averaging 1,878,000.000 USD th from Jun 2015 to Sep 2018, with 14 observations. The data reached an all-time high of 3,343,000.000 USD th in Dec 2016 and a record low of 648,000.000 USD th in Mar 2018. US: PFE: Revenue (External): Essential Health Product: International: Developed Rest of World data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Last Frequency Range
1,402,000.00 Jun 2018 quarterly Jun 2015 - Jun 2018

View United States's US: PFE: Revenue (External): Essential Health Product: International: Developed Rest of World from Jun 2015 to Jun 2018 in the chart:

United States US: PFE: Revenue (External): Essential Health Product: International: Developed Rest of World

United States US: PFE: Revenue (External): Essential Health Product: International: Emerging markets

2015 - 2018 | Quarterly | USD th | Pfizer Incorporation

US: PFE: Revenue (External): Essential Health Product: International: Emerging markets data was reported at 5,775,000.000 USD th in Sep 2018. This records an increase from the previous number of 3,898,000.000 USD th for Jun 2018. US: PFE: Revenue (External): Essential Health Product: International: Emerging markets data is updated quarterly, averaging 4,431,500.000 USD th from Jun 2015 to Sep 2018, with 14 observations. The data reached an all-time high of 7,116,000.000 USD th in Dec 2015 and a record low of 1,610,000.000 USD th in Mar 2016. US: PFE: Revenue (External): Essential Health Product: International: Emerging markets data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Last Frequency Range
3,898,000.00 Jun 2018 quarterly Jun 2015 - Jun 2018

View United States's US: PFE: Revenue (External): Essential Health Product: International: Emerging markets from Jun 2015 to Jun 2018 in the chart:

United States US: PFE: Revenue (External): Essential Health Product: International: Emerging markets

United States US: PFE: Revenue (External): Essential Health Product: US

2015 - 2018 | Quarterly | USD th | Pfizer Incorporation

US: PFE: Revenue (External): Essential Health Product: US data was reported at 4,859,000.000 USD th in Sep 2018. This records an increase from the previous number of 3,379,000.000 USD th for Jun 2018. US: PFE: Revenue (External): Essential Health Product: US data is updated quarterly, averaging 4,849,500.000 USD th from Jun 2015 to Sep 2018, with 14 observations. The data reached an all-time high of 9,596,000.000 USD th in Dec 2016 and a record low of 1,731,000.000 USD th in Mar 2018. US: PFE: Revenue (External): Essential Health Product: US data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Last Frequency Range
3,379,000.00 Jun 2018 quarterly Jun 2015 - Jun 2018

View United States's US: PFE: Revenue (External): Essential Health Product: US from Jun 2015 to Jun 2018 in the chart:

United States US: PFE: Revenue (External): Essential Health Product: US

United States US: PFE: Revenue (External): Innovative Health Product: International

2014 - 2018 | Quarterly | USD th | Pfizer Incorporation

US: PFE: Revenue (External): Innovative Health Product: International data was reported at 6,982,000.000 USD th in Jun 2018. This records an increase from the previous number of 3,285,000.000 USD th for Mar 2018. US: PFE: Revenue (External): Innovative Health Product: International data is updated quarterly, averaging 7,974,500.000 USD th from Sep 2014 to Jun 2018, with 16 observations. The data reached an all-time high of 13,047,000.000 USD th in Dec 2014 and a record low of 2,767,000.000 USD th in Mar 2015. US: PFE: Revenue (External): Innovative Health Product: International data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Last Frequency Range
6,982,000.00 Jun 2018 quarterly Sep 2014 - Jun 2018

View United States's US: PFE: Revenue (External): Innovative Health Product: International from Sep 2014 to Jun 2018 in the chart:

United States US: PFE: Revenue (External): Innovative Health Product: International

United States US: PFE: Revenue (External): Innovative Health Product: International: Developed EU

2014 - 2018 | Quarterly | USD th | Pfizer Incorporation

US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data was reported at 2,835,000.000 USD th in Jun 2018. This records an increase from the previous number of 1,314,000.000 USD th for Mar 2018. US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data is updated quarterly, averaging 3,304,000.000 USD th from Sep 2014 to Jun 2018, with 16 observations. The data reached an all-time high of 5,806,000.000 USD th in Dec 2014 and a record low of 1,174,000.000 USD th in Mar 2015. US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Last Frequency Range
2,835,000.00 Jun 2018 quarterly Sep 2014 - Jun 2018

View United States's US: PFE: Revenue (External): Innovative Health Product: International: Developed EU from Sep 2014 to Jun 2018 in the chart:

United States US: PFE: Revenue (External): Innovative Health Product: International: Developed EU

United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World

2014 - 2018 | Quarterly | USD th | Pfizer Incorporation

US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data was reported at 1,753,000.000 USD th in Jun 2018. This records an increase from the previous number of 812,000.000 USD th for Mar 2018. US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data is updated quarterly, averaging 1,980,000.000 USD th from Sep 2014 to Jun 2018, with 16 observations. The data reached an all-time high of 3,433,000.000 USD th in Dec 2017 and a record low of 707,000.000 USD th in Mar 2015. US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Last Frequency Range
1,753,000.00 Jun 2018 quarterly Sep 2014 - Jun 2018

View United States's US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World from Sep 2014 to Jun 2018 in the chart:

United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World

United States US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets

2014 - 2018 | Quarterly | USD th | Pfizer Incorporation

US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data was reported at 2,394,000.000 USD th in Jun 2018. This records an increase from the previous number of 1,158,000.000 USD th for Mar 2018. US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data is updated quarterly, averaging 2,571,000.000 USD th from Sep 2014 to Jun 2018, with 16 observations. The data reached an all-time high of 4,381,000.000 USD th in Dec 2017 and a record low of 872,000.000 USD th in Mar 2016. US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Last Frequency Range
2,394,000.00 Jun 2018 quarterly Sep 2014 - Jun 2018

View United States's US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets from Sep 2014 to Jun 2018 in the chart:

United States US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets

United States US: PFE: Revenue (External): Innovative Health Product: US

2014 - 2018 | Quarterly | USD th | Pfizer Incorporation

US: PFE: Revenue (External): Innovative Health Product: US data was reported at 9,121,000.000 USD th in Jun 2018. This records an increase from the previous number of 4,544,000.000 USD th for Mar 2018. US: PFE: Revenue (External): Innovative Health Product: US data is updated quarterly, averaging 9,025,500.000 USD th from Sep 2014 to Jun 2018, with 16 observations. The data reached an all-time high of 18,460,000.000 USD th in Dec 2017 and a record low of 2,972,000.000 USD th in Mar 2015. US: PFE: Revenue (External): Innovative Health Product: US data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Last Frequency Range
9,121,000.00 Jun 2018 quarterly Sep 2014 - Jun 2018

View United States's US: PFE: Revenue (External): Innovative Health Product: US from Sep 2014 to Jun 2018 in the chart:

United States US: PFE: Revenue (External): Innovative Health Product: US
US: PFE: Revenue (External): Essential Health Product: International
US: PFE: Revenue (External): Essential Health Product: International: Developed EU
US: PFE: Revenue (External): Essential Health Product: International: Developed Rest of World
US: PFE: Revenue (External): Essential Health Product: International: Emerging markets
US: PFE: Revenue (External): Essential Health Product: US
US: PFE: Revenue (External): Innovative Health Product: International
US: PFE: Revenue (External): Innovative Health Product: International: Developed EU
US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World
US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets
US: PFE: Revenue (External): Innovative Health Product: US
Unlimited access tailored to your data needs
Flexible monthly access to CEIC data